Johns Hopkins scientists develop mRNA "booster" as potential new way to treat rare genetic diseases marked by too low levels ...

This acquisition combines Officinae Bio's AI-enabled mRNA design platforms with Maravai and TriLink BioTechnologies' leading drug substance manufacturing capabilities, providing customers ...

On February 24, Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) announced that it completed its acquisition of Officinae Bio’s DNA and RNA business, integrating AI-driven mRNA design technology with ...

Johns Hopkins Medicine laboratory scientists say they have developed a potential new way to treat a variety of rare genetic ...

“By integrating our expertise in mRNA design and nanoparticle delivery with IPA’s cutting-edge antibody discovery and engineering capabilities, we can address longstanding challenges in ...

The cancer vaccine candidate is manufactured with mRNA specific to these neoantigens found in that individual’s tumor. The process to design and manufacture individualized vaccines for cancer ...

Everest Medicines has established a fully integrated and clinically validated mRNA platform, encompassing antigen design, mRNA sequence optimization, LNP delivery system, and GMP production ...

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced a strategic collaboration with RIBOPRO, a ...